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Abstract 
Aim:  
To discuss the pathophysiology of iron metabolism in chronic heart failure (CHF), the current 
knowledge of the efficacy of intravenous (IV) iron therapy in patients with CHF and identify points of 
controversy as well as highlight areas for future research. 
 
Discussion:  
Iron deficiency is a recognised complication of many chronic conditions. Numerous studies have 
reported that iron deficiency is highly prevalent in patients with CHF and is associated with exercise 
intolerance, reduced quality of life, and increased risk of hospitalisation and mortality. Several small 
studies have demonstrated IV iron to be associated with improvements in symptoms, exercise 
capacity, quality of life, renal function, New York Heart Association (NYHA) functional class and left 
ventricular ejection fraction (LVEF), and reduction in NT-pro-brain natriuretic peptide (NT-proBNP) in 
patients with CHF and iron deficiency. Two larger scale trials confirming these results (FAIR-HF and 
CONFIRM-HF) have led to guideline recommendations that IV iron therapy should be considered in 
patients with CHF with reduced ejection fraction and iron deficiency (serum ferritin <100μg/L, or 
ferritin between 100-299μg/L and transferrin saturation <20%) in order to provide symptomatic 
relief and improve exercise capacity and quality of life.  
 
Conclusion:  
IV iron therapy improves symptoms, exercise capacity, and quality of life, at least in the short to 
intermediate time.  However, there is still currently no standardised criteria used to define iron 
deficiency and the underlying mechanism of iron deficiency in CHF remains incompletely 
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understood. Further work is required to improve the ability to identify iron deficiency in patients 
with CHF and evaluate the effect of iron repletion on hard end-points including hospitalisation and 
mortality.     
 
Introduction    
                Worldwide approximately one-third of the general population is affected by iron deficiency, 
making it the most common nutritional disorder.[1-3] Iron deficiency is a recognised complication of 
chronic conditions such as inflammatory bowel, rheumatoid, and chronic kidney disease.[4-6] As an 
essential micronutrient, iron has a central role in many metabolic processes. Due to its ability to 
switch between two oxidative states, ferrous (Fe2+) and ferric (Fe3+), iron is an efficient cofactor for 
several enzymes which help catalyse numerous biochemical reactions.[7-8] Iron is a component of 
haemoglobin, which is crucial for oxygen transport to tissues. It also plays a role in oxygen storage 
(myoglobin), oxidative metabolism (component of oxidative enzymes and respiratory chain 
proteins), and is involved in the synthesis and breakdown of carbohydrates, lipids, and nucleic 
acids.[7-10]  
 
It is increasingly recognised that many patients with chronic heart failure (CHF) have 
associated iron deficiency. These patients experience worse symptoms compared to those who are 
iron replete and are at a higher risk of morbidity and mortality. This article discusses the prevalence 
of iron deficiency in heart failure, its underlying pathophysiology, and examines current clinical 
practice in the management of iron-deficient CHF patients. This article also identifies points of 
controversy and highlights areas for future research.    
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Iron metabolism and aetiology of iron deficiency in chronic heart failure 
 Although iron plays an important physiological role, an excess leads to significant toxicity 
and end-organ damage as seen in disease states of iron overload and inherited defects in iron 
metabolism such as hereditary haemochromatosis. As there is no specific mechanism for iron 
excretion, iron absorption and subsequent metabolism is tightly regulated. Homeostasis is then 
maintained by loss of iron through the turnover of skin and gut epithelial cells and bleeding.[11] 
 
 Iron is primarily absorbed in the duodenum and jejunum via the divalent metal transporter 
protein on the luminal cell membrane. Ferric iron is reduced to its ferrous form by the enzyme ferric 
reductase and cytoplasmic ferrous iron is either packaged as ferritin for intracellular storage or 
transported across the basolateral membrane into the circulation. This process involves oxidisation 
back to its ferric form by the enzyme hephaestin oxidase and export through ferroportin iron 
channels allowing absorbed iron to be transported through the circulation bound to transferrin.[11] 
 
 Circulating iron is avidly taken up by hepatocytes, splenic cells, and bone marrow. Iron is 
incorporated into haem for bone marrow haematopoiesis or packaged as ferritin for iron storage 
particularly within the liver and spleen. Senescent erythrocytes are broken down by 
reticuloendothelial macrophages in the liver and spleen releasing further iron for either storage or 
circulation.[11-12]  
 
 Distinguishing between stored and circulating iron is key to characterising iron deficiency, 
which can be classified as either absolute or functional.[12-13] Absolute deficiency represents a 
depletion of iron stores whilst functional deficiency includes: 
1. Normal iron stores but impaired mobilisation of iron into the circulation thereby 
restricting iron availability for cell metabolism and erythropoiesis. 
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2. An insufficient supply of iron to meet the demands of enhanced erythropoiesis 
brought about by either anaemia of another cause or excessive endogenous erythropoietin 
production.  
 
Although ferritin is the predominant form of intracellular stored iron, a proportion of this 
enters the circulation. Serum ferritin levels can therefore serve as a surrogate marker of iron stores. 
Systemic inflammation however, results in the release of acute phase reactants, including ferritin, 
therefore limiting the validity of the relationship between serum ferritin levels and levels of stored 
iron in many chronic conditions. Perhaps more important is the amount of circulating iron available 
for cell metabolism. This can be estimated as a percentage of circulating transferrin saturated with 
iron (TSAT).
[13] 
 
Many pro-inflammatory cytokines have been implicated in the progression of CHF. Of these, 
the most important ones appear to be tumour necrosis factor α (TNFα), interleukin (IL) 1, and IL-6.[14] 
In mice models, both TNFα and IL-1 induce the synthesis of ferritin by macrophages and 
hepatocytes.[15-16] Divalent metal transporter 1 (DMT1), a transmembrane iron transport protein, is 
involved in the uptake of iron by macrophages and is up-regulated in the presence of TNFα, 
interferon-γ, and lipopolysaccharide.[17-18] These pro-inflammatory cytokines also stimulate retention 
of iron in macrophages by down-regulating the expression of ferroportin.[18] Ferroportin is therefore 
involved in the release of iron from macrophages as well as the transfer of absorbed iron to the 
systemic circulation.[19] The discovery of hepcidin, an acute-phase protein, furthered the 
understanding of the relationship between the inflammatory immune response and iron 
homeostasis. Both IL-6 and lipopolysaccharide induce hepcidin expression and production in the 
liver. Results from mice models suggest that hepcidin may be centrally involved in the diversion of 
iron traffic by reducing duodenal iron absorption across the basolateral enterocyte membrane and 
blocking iron release from macrophages.[20] Consequently there is limited iron available for 
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utilisation by erythroid progenitor cells, thus resulting in iron-restricted erythropoiesis as well as 
adversely impacting on the other key physiological roles of iron.  
 
However, iron metabolism has yet to be fully investigated in patients with CHF and it 
remains unknown to what extent data from animal models can be extrapolated and applied to the 
clinical setting. It is tempting to link iron deficiency in CHF with associated inflammation and to 
suggest that hepcidin may have a central role in the inhibition of iron absorption.[21] Recent studies, 
however, found rather low circulating levels of hepcidin in patients with CHF and reported no 
association between levels of pro-inflammatory cytokines (such as IL-6) and overexpression of 
hepcidin.[22-24] Although markers of inflammation increased with worsening functional class, the 
inverse was true for hepcidin despite iron deficiency and iron-restricted erythropoiesis becoming 
increasingly common. Importantly, circulating levels of erythropoietin are often raised in heart 
failure, being higher in patients with worse functional class and are correlated with adverse 
prognosis.[12] Erythropoietin is a powerful suppressor of hepcidin production and this may to some 
extent explain the lower levels observed in those with worse symptoms. The underlying mechanism 
of iron deficiency in CHF remains incompletely understood and further work is needed to fully 
elucidate the precise pathophysiology, and this in turn may influence treatment strategies. 
 
 
Diagnosing iron deficiency 
As outlined above, iron exists in stored intracellular, circulating, and utilised forms; the latter 
predominantly within erythrocyte haemoglobin. Levels of all forms vary considerably and movement 
between them involves complex regulation in response to changing metabolic requirements and 
various pathophysiological processes. An optimal diagnostic test would simply and accurately 
measure all forms of iron as well as total body iron levels. Unfortunately, no such test exists. Table 1 
summarises the various blood tests used to diagnose iron deficiency.  
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Bone marrow biopsy is considered the 'gold standard' for evaluating iron status. This has the 
advantage of directly measuring iron stored within bone marrow and available for haematopoeisis. 
However, it is an invasive, uncomfortable and relatively complicated test to perform therefore 
significantly limiting its clinical applicability. In the absence of a single diagnostic test we rely on a 
combination of serum biomarkers. The most widely used of these is ferritin. Intracellular iron is 
stored as a protein bound complex known as ferritin. Although intracellular levels cannot be 
measured, a proportion crosses the cell membrane and enters the circulation. Quantification of 
circulating levels serve as a surrogate measure of iron stores. A low ferritin indicates iron deficiency. 
Ferritin however is also an acute phase protein released from the liver in response to inflammation 
thereby significantly reducing its diagnostic accuracy – in particular a ‘normal’ ferritin does not 
exclude iron deficiency in the context of co-existing inflammatory immune activation. Circulating 
iron is also measurable. However, this has a number of limitations. Serum iron levels vary 
considerably depending on intake and physiological requirements and may be maintained even as 
iron stores become significantly depleted. Circulating iron is found predominantly bound to its 
specific carrier protein, transferrin. Levels of circulating iron are therefore strongly influenced by 
levels of serum transferrin. Furthermore, transferrin is produced in response to low iron stores and 
increasing demands. Measurements of either serum iron or circulating transferrin alone therefore 
poorly reflect iron levels. The percentage of transferrin saturated with iron can also be measured. In 
iron deficiency, iron levels fall whilst transferrin increases resulting in fewer binding sites occupied 
and lower percentage transferrin saturation.  
 
The major studies of iron deficiency in heart failure adopt a definition combining ferritin and 
transferrin saturations. Although in physiological circumstances, a ferritin above 30ng/L is 
considered normal, in an inflammatory state this cut off results in poor sensitivity. Instead, a ferritin 
of <100ng/L or a value of between 100 and 300ng/L with transferrin saturations <20% have been 
deemed to suggest iron deficiency. 
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Prevalence and prognosis of iron deficiency in heart failure 
                In recent years, there has been increased focus on the clinical importance of iron deficiency 
in patients with CHF. It is a frequent co-morbidity with varying prevalence depending on study 
criteria and the definition of iron deficiency used. For example, in one study of 1506 stable CHF 
patients with both preserved and reduced left ventricular systolic function, 50% were reported to be 
iron deficient.[25] When analysed according to haemoglobin level, 46% of those without anaemia and 
61% of those with anaemia were iron deficient.[25] These results are similar to a recently published 
study of 4456 patients referred to a single outpatient heart failure service, which identified iron 
deficiency in 43-68% of patients with anaemia and 14-35% of those with a normal haemoglobin 
depending on the definition of iron deficiency used.[26] There has only been one published study 
using the gold standard technique of bone marrow analysis, which examined 37 anaemic patients 
with advanced severe heart failure and demonstrated iron deficiency in 73%.[27]  
 
                Many studies have shown that iron deficiency is associated with exercise intolerance, 
reduced quality of life, and increased risk of hospitalisation and mortality in CHF patients.[28-30] 
Although iron deficiency is frequently related to anaemia, it is an independent predictor of symptom 
severity, exercise tolerance, and quality of life irrespective of haemoglobin status.[25,29-30] One study 
analysed 3 years of follow-up of 546 patients with CHF secondary to left ventricular systolic 
dysfunction (LVEF ≤ 45%) attending outpatient clinics or admitted to a tertiary referral cardiology 
centre.[29] Event-free survival (event defined as all-cause death and transplantation) was 54% in 
those with iron deficiency versus 67% in those without (Figure 1).[29] Analysis of a cohort of patients 
with both preserved and reduced left ventricular systolic function demonstrated an association 
between both anaemia and iron deficiency with higher New York Heart Association (NYHA) 
functional class. As seen in Figure 2, iron deficiency was associated with increased mortality, with an 
even stronger relationship when associated with anaemia.[25]  
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Therapeutic interventions: 
                Prior to considering specific treatment of iron deficiency, it is worth discussing the role of 
erythropoeisis stimulating agents (ESA) in patients with CHF. Recognising the association of anaemia 
with adverse outcomes in CHF, several small studies evaluated the potential benefit of ESA with 
encouraging results that suggested improvement in symptoms and reduction in hospital 
admissions.[31-35] These led to the RED-HF trial,[36] a randomised, double-blind study designed to 
ascertain whether treatment with the ESA darbepoietin alfa improves clinical outcomes in CHF 
patients with anaemia. This double blind study of 2278 patients with CHF (LVEF ≤ 40%) and mild-to-
moderate anaemia (defined as haemoglobin between 9.0 and 12.0g/dL) were recruited and assigned 
to receive either darbepoietin alfa or placebo. Participants in the active treatment arm were given 
the drug to achieve a haemoglobin target of 13.0g/dL. The primary endpoint was a composite of 
death from any cause or first hospitalisation for worsening heart failure. The primary endpoint 
occurred in 576 patients (50.7%) of 1136 patients in the active treatment arm and in 565 (49.5%) in 
the placebo group (P=0.87). A total of 42 patients (3.7%) in the darbepoietin alfa group experienced 
a fatal or non-fatal stroke as opposed to 31 patients (2.7%) in the placebo group (P=0.23). Reports of 
thromboembolic adverse events were received from 153 patients (13.5%) and 114 patients (10.0%) 
from the darbepoietin alfa group and placebo group, respectively (P=0.01). Darbepoietin alfa 
therefore did not reduce the rate of mortality or hospitalisation among patients with CHF and 
associated anaemia but conferred a significant increase in the risk of thromboembolic events. This 
study served to eliminate erythropoietin as a standard treatment for anaemia in patients with CHF. 
 
Iron replacement 
                Several small studies reported that intravenous (IV) iron was associated with improvements 
in symptoms, exercise capacity, quality of life, renal function, NYHA functional class and LVEF, and 
reduction in NT-proBNP in CHF patients with iron deficiency anaemia.[37-39] Further data supporting 
benefit on exercise capacity have come from a recent study which demonstrated a significant 
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improvement in peak oxygen uptake (VO2) among symptomatic patients with stable heart failure 
treated with IV iron for 24 weeks as compared with placebo (P=0.02).[40] In contrast, oral iron 
appears to have little effect on oxygen consumption or iron stores in patients with CHF.[41] This is 
likely due to the impaired duodenal absorption of iron in the context of the chronic inflammatory 
state described above.  
     
            To date, there have been two larger-scale clinical trials which reported the beneficial effects 
of IV iron therapy in CHF patients with iron deficiency.[21,42] The FAIR-HF trial[42] was a randomised, 
double-blind study designed to determine whether the administration of IV iron (ferric 
carboxymaltose) conferred symptomatic benefit in iron-deficient CHF patients, either with or 
without anaemia. In this study, 459 patients with CHF and NYHA functional class II or III were 
enrolled. Cut-off points for LVEF were ≤ 40% and ≤ 45% for NYHA class II and III respectively. Iron 
deficiency was defined as ferritin < 100µg/L, or between 100 and 299µg/L with transferrin saturation 
< 20%. The subjects were randomly assigned to receive either IV ferric carboxymaltose or saline 
(placebo). The primary endpoints were the self-reported Patient Global Assessment and NYHA 
functional class, both recorded at week 24. Among the patients who were given ferric 
carboxymaltose, 50% reported being much or moderately improved, and 47% were in NYHA 
functional class I or II. In comparison, 28% of patients in the placebo arm reported being much or 
moderately improved, and 30% were in NYHA functional class I or II (P<0.001). No significant 
differences were found between anaemic and non-anaemic patients (anaemia defined as 
haemoglobin < 12.0g/dL for both men and women). The second study, known as CONFIRM-HF 
trial,[21] was a multi-centre, double-blind, placebo-controlled trial designed to evaluate the effects 
and safety (to one year) of IV iron therapy in iron-deficient CHF patients. A total of 304 CHF patients 
with LVEF ≤ 45% were recruited with the same definitions of iron deficiency as in FAIR-HF. Patients 
were randomised in a 1 : 1 ratio to receive either IV ferric carboxymaltose or saline (placebo) for 52 
weeks. The primary endpoint was the change in 6-minute-walk-test (6MWT) distance from baseline 
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to week 24. IV ferric carboxymaltose was associated with significantly greater improvement in 
6MWT distance at week 24 of 33 ± 11m over the placebo group (P=0.002). The beneficial effects of 
iron therapy were sustained throughout the period of study. Furthermore, although it was not 
powered to evaluate this, IV iron was associated with a reduction in the risk of hospitalisation for 
worsening heart failure (HR 0.39, 95% CI 0.19-0.82, P – 0.009). 
 
A recent meta-analysis by Jankowska et al.[43] examined evidence from five randomised 
controlled trials,[21, 39, 42, 44-45] involving a total of 851 patients – the majority being from FAIR-HF and 
CONFIRM-HF. IV iron therapy improved symptoms, exercise capacity, quality of life, and clinical 
outcomes, regardless of concomitant anaemia. Interestingly, the risk of cardiovascular 
hospitalisation, heart failure hospitalisation, cardiovascular death, and all-cause death appeared to 
be significantly reduced by IV iron therapy. Table 2 summarises the key results from the meta-
analysis. 
 
Current guidelines 
In the latest clinical guideline published by the Scottish Intercollegiate Guidelines Network 
(SIGN) on management of CHF,[46] patients with reduced ejection fraction, NYHA class III with an 
LVEF ≤ 45%, or NYHA class II, LVEF ≤ 40%, with a haemoglobin level of 9.5 to 13.5g/dL and iron 
deficiency (defined as ferritin < 100µg/L, or transferrin saturation < 20% with ferritin 100-300µg/L) 
should be considered for IV iron therapy. IV ferric carboxymaltose is also shown to be cost-effective 
(£12,482 per QALY gained).[47] In addition, the SIGN guidelines state that erythropoietin is not 
recommended for CHF patients with reduced ejection fraction and anaemia, mainly due to the 
absence of beneficial effects and the increased risk of thromboembolic adverse events.[46]     
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The European Society of Cardiology (ESC) has also recently recommended that IV iron be 
considered in symptomatic patients with heart failure with reduced ejection fraction and iron 
deficiency (same definitions applied as the SIGN guidelines) – Class IIa recommendation and Level A 
evidence. The primary purpose of this recommendation is for symptom alleviation and to improve 
exercise capacity and quality of life.[48} 
 
 The latest update published by the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America 
(ACC/AHA/HFSA) recommended that IV iron may be considered in patients with NYHA class II and III 
and iron deficiency (ferritin < 100ng/mL or 100-300ng/mL if transferrin saturation < 20%) to improve 
functional status and quality of life (Class IIb recommendation and Level B-R evidence).[49] However, 
the report also stated that a strong recommendation for IV iron replacement can only be made once 
results from a well-designed trial evaluating its effects on morbidity and mortality are available.  
 
Future challenges 
                Major gaps of knowledge still exist. Although serum ferritin has been used in several of the 
studies, increasing amounts of data suggest that serum ferritin is not a robust indicator of iron 
deficiency.[26] Patients with CHF are less likely to have a low serum ferritin compared to patients 
without CHF. This may be attributed to the fact that ferritin is an acute-phase reactant which may be 
elevated in response to the underlying inflammatory process in CHF.[14-20] Consequently, iron 
deficiency may be missed if based on serum ferritin concentration as high levels of serum ferritin 
may reflect inflammation rather than iron repletion. Many patients with serum ferritin < 100µg/L 
were also found not to have anaemia, thus suggesting a poor correlation between serum ferritin 
levels and prevalence of anaemia.[26] Therefore, the validity of serum ferritin as a tool used to define 
iron deficiency is questionable and further work is needed to evaluate other haematinic factors 
which may potentially be a better indicator of iron deficiency.  
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                In addition, the longer-term impact of iron repletion on CHF hospitalisation, overall 
hospitalisation (used as an index of both morbidity and cost-effectiveness), cardiovascular mortality, 
and safety is still poorly understood.[50] An ongoing UK based study, IRONMAN,[50] is a prospective, 
randomised open-label, blinded endpoint trial aiming to evaluate these issues. The primary objective 
is to compare the additional effect of an IV iron regimen (iron isomaltoside-1000) when added to 
standard guideline-indicated therapy on cardiovascular mortality and recurrent hospitalisations due 
to heart failure in patients with CHF secondary to left ventricular systolic dysfunction and iron 
deficiency. A total of 1300 patients will be recruited with the study period planned to last for 
approximately 4.5 years. Further outcome studies are planned in Germany and the United States. 
 
Conclusion 
               Iron deficiency is very common in CHF and associated with an increased morbidity and 
mortality. IV iron therapy improves symptoms, exercise capacity, and quality of life, at least in the 
short to intermediate time.  However, there is still currently no standardised criteria used to define 
iron deficiency and the underlying mechanism of iron deficiency in CHF remains incompletely 
understood. Further work is required to improve the ability to identify iron deficiency in patients 
with CHF and evaluate the effect of iron repletion on hard end-points including hospitalisation and 
mortality.    
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Table 1: Summary of blood tests used to diagnose iron deficiency 
Test Strengths Limitations 
Ferritin 
1. Measures stored iron 
2. Not affected by short term variations 
in iron intake 
1. Affected by inflammatory states 
limiting sensitivity 
2. Affected by liver disease 
Serum iron 1. Direct measurement 
1. Does not reflect iron stores 
2. Highly variable with intake and 
metabolic requirements 
Serum 
transferrin 
1. Reflects varying metabolic 
requirements 
2.Not affected by inflammatory states 
1. Falsely low in liver disease 
2. Not a direct measurement of iron 
levels 
Transferrin 
saturations 
1. Not affected by inflammatory states 
2. Measures transported iron available 
for cell uptake 
1. Does not directly measure iron 
stores 
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Table 2. Summary of results of the meta-analysis of iron therapy in heart failure by Jankowska et 
al.[43]. (EQ-5D – European Quality of Life, HF – Heart failure, KCCQ – Kansas City Cardiomyopathy 
Questionnaire, LVEF – Left Ventricular Ejection Fraction, MLHFQ – Minnesota Living with Heart 
Failure Questionnaire, 6MWT – 6 Minute Walking Test, N/A - Not applicable, PGA – Patient Global 
Assessment) 
 
  
Tobili[44] 
FERRIC-
HF[39]  
FAIR-
HF[42] 
IRON-
HF[45] 
CONFIRM-
HF[21] 
Meta-
analysis[43
] 
Number 
randomised 
(n=) 
40 35 459 16 301 851 
Follow up 
period 
5 months 
after 
treatment 
2 weeks 
after 
treatment 
24-26 weeks 3 months 52 weeks - 
Outcome 
OR, 95% 
CI 
OR, 95% 
CI 
OR, 95% 
CI 
OR, 95% 
CI 
OR, 95% CI 
OR, 95% 
CI 
All cause 
death 
N/A 
1.47 (0.06, 
38.91) 
0.62 
(0.17;2.36) 
1.25 
(0.09;17.6
5) 
0.85 
(0.38;1.91) 
0.83 
(0.43;1.59) 
p=0.5671 
Cardiovascular 
death 
N/A 
1.47 (0.06; 
38.91 
0.50 (0.12; 
2.02 
N/A 
0.92 (0.39; 
2.15) 
0.80 (0.39; 
1.63) 
p=0.5405 
All-cause 
death or 
cardiovascular 
hospitalisation 
N/A 
0.24 (0.03; 
1.73) 
0.44 (0.24; 
0.84) 
N/A 
0.45 (0.28; 
0.73) 
0.44 (0.30; 
0.54) 
p<0.0001 
Cardiovascular 
death or 
hospitalisation 
for worsening 
heart failure 
N/A N/A 
0.41 (0.18; 
0.93) 
N/A 
0.38 (0.21; 
0.68) 
0.39 (0.24; 
0.63) 
p=0.0001 
HF 
hospitalisation 
0.07 (0.000; 
1.34) 
0.20 (0.02; 
2.43) 
0.38 (0.14; 
1.04) 
N/A 
0.27 (0.13; 
0.56) 
0.28 (0.16; 
0.50) 
p<0.0001 
  
Mean 
difference 
between 
groups 
Mean 
difference 
between 
groups 
Mean 
difference 
between 
groups 
Mean 
difference 
between 
groups 
Mean 
difference 
between 
groups (95% 
Mean 
difference 
between 
groups 
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(95% CI) (95% CI) (95% CI) (95% CI) CI) (95% CI) 
6MWT distance  N/A N/A 
28.4 (13.95; 
42.85) 
N/A 
38.40 (12.80; 
64.00) 
30.82 
(18.23; 
43.40) 
p<0.0001 
NYHA class  
-1.30 (-
1.77; -0.83) 
-0.60 (-
0.96; -
0.24) 
-0.25 (-
0.37; -0.13) 
N/A 
-0.28 (-0.49; 
-0.06) 
-0.54 (-0.87; 
-0.21) 
p=0.0013 
LVEF 
-6.4 (-9.32; 
-3.48) 
1.0 (-2.80; 
4.80) 
N/A N/A N/A 
-2.8 (-10.05; 
4.45) 
p=0.4485 
EQ-5D score N/A N/A 
5.70 (2.04; 
9.36) 
N/A 
2.4 (-1.34; 
6.14) 
4.07 90.84; 
7.310 
p=0.0136 
KCCQ score N/A N/A 
6.60 (2.72; 
10.48) 
N/A 
4.40 (0.45; 
8.35) 
5.52 (2.75; 
8.29) 
p,0.0001 
PGA N/A 
1.70 (0.58; 
2.82) 
0.63 (0.35; 
0.91) 
N/A 
0.52 (0.06; 
0.98) 
0.70 (0.31; 
1.09) 
p=0004 
MLHFQ score 
-20.00 (-
24.04; -
15.96) 
13.00 (-
27.17; 
1.17) 
N/A N/A N/A 
-19.47 (-
23.36; -
15.59) 
p<0.0001 
 
 
 
Figure Legends 
Figure 1. 3-year event free survival (all-cause death and transplantation) in 546 patients with chronic 
heart failure secondary to left ventricular systolic dysfunction with versus without iron deficiency. 
(From Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron 
deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010; 31(15): 
1872-80; Used with permission) 
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Figure 2 A. The presence of iron deficiency is associated with reduced survival in chronic heart 
failure patients with both preserved and impaired left ventricular systolic function. B. Iron deficiency 
and anaemia are cumulatively associated with reduce survival with the effect of iron deficiency 
appearing to have greater significance to anaemia alone. (From Klip IT, Comin-Colet J, Voors AA, 
Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international 
pooled analysis. Am Heart J. 2013; 165(4): 575-82.e3.; Used with permission)  
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